CA2383636C - Collagen membrane for mucosa regeneration - Google Patents
Collagen membrane for mucosa regeneration Download PDFInfo
- Publication number
- CA2383636C CA2383636C CA2383636A CA2383636A CA2383636C CA 2383636 C CA2383636 C CA 2383636C CA 2383636 A CA2383636 A CA 2383636A CA 2383636 A CA2383636 A CA 2383636A CA 2383636 C CA2383636 C CA 2383636C
- Authority
- CA
- Canada
- Prior art keywords
- collagen
- membrane
- layer
- mucosa
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Abstract
Healing of mucosa injury is promoted by applying thereto a membrane of purified collagen material derived from natural collagen-containing tissue.
Description
COLLAGEN MEMBRANE FOR MUCOSA REGENERATION
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates generally to methods for regeneration of mucosa.
Discussion of the Background Art The use of split thickness skin grafts and oral mucosal free grafts in vestibular deepening and other types of vestibuloplasty surgery in the oral cavity has been an established procedure for some time. In addition, the use of free mucosal grafts taken from the palate and from the buccal mucosa has been used in re-establishing attached mucosal surfaces in edentulous alveolar ridge areas particularly in conjunction with the use of root form implants.
While such grafting procedures are well established, the development of an effective alloplastic or xenogeniec substitute graft material for the reconstruction and regeneration of normal mucous membrane would bring about a much wider application of vestibuloplasty surgical procedures.
There remains a need in the art for improvements in promoting regeneration of mucosa in general and, in particular, following vestibuloplasty surgical procedures.
SUMMARY OF THE INVENTION
In accordance with the present invention, mucosa regeneration is promoted utilizing a membrane comprised of a purified collagen material derived from natural collagen-containing tissue.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a plan view showing a patch of collagen membrane material covering an area of mucosa to be treated.
FIG. 2 is a sectional side view showing a membrane for use in accordance with the present invention.
FIG. 3 is a sectional side view showing another membrane for use in accordance with the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention provides a method for promoting regeneration of mucosa. While the method is described in connection with promoting regeneration of mucosa in the oral cavity following specific types of oral surgery, it will be appreciated that the method can be employed to promote regeneration of mucosa in any part of the body having damaged mucosal tissue.
In preferred embodiments, a method of promoting regeneration of mucosa includes the steps of covering the area to be treated with a patch comprised of a sheet of collagen membrane material, wherein the collagen membrane material is comprised of at least one layer having a smooth face and a fibrous face opposite the smooth face, the fibrous face allowing cell growth thereon, wherein the collagen membrane preferably further comprises a second layer predominantly of collagen II or a mixture of collagen I and III having an open sponge-like texture. The patch is fixed over a defect in the mucosa, preferably with sutures, and the mucosa is allowed to regenerate.
In accordance with the present invention, as shown in Fig. 1, a defect in a mucosal surface M is repaired by placing a patch 10 over the defect and securing the patch to margins of the mucosal surface around the defect. The patched area is then allowed to regenerate mucosa. In Fig.
1, the patch 10 is shown secured by sutures 12 to the mucosal surface M. Alternatively, the patch can be secured over the defect by adhesively bonding the patch to the surrounding host mucosa or other structures surrounding the area to be treated, for example, utilizing an organic glue as is known in the art, or any other suitable method.
The patch 10 is formed of a preparation comprising a collagen membrane with appropriate pliability to conform closely to the shape of the mucosal surface against which it is placed. In a preferred embodiment, the collagen membrane includes at least one collagen layer having sufficient strength to accommodate suturing to the mucosa and to protect the mucosal surface from trauma during the healing process.
A first embodiment of a collagen membrane for use as a patch in accordance with the present invention is shown in Fig. 2 at 14. The membrane 14 includes a single collagen layer 16 having a smooth face 18 on one side and a textured or fibrous face 20 on the other side opposite the smooth face. The smooth face 18 is preferably non-porous to provide mechanical protection, for example when eating. The fibrous face 20 is configured to allow cell growth thereon. In use, the smooth face preferably is oriented away from the area to be treated, and the fibrous face preferably is oriented toward the area to be treated.
In preferred embodiments, the collagen layer 16 is predominantly collagen I, collagen III or a mixture thereof.
One suitable material for this layer is Biogide , from Ed.
Geistlich 561-me AG fUr Chemische Industrie, the assignee of the present invention. The Biogide material is described in U.S. Patent No. 5,837,278.
Fig. 3 shows a multi-layer collagen membrane 14' that can be used as a patch in accordance with the present invention. This membrane includes a first collagen layer 16 as shown in Fig. 2, and further includes a second collagen layer 22 having an open sponge-like texture. The second collagen layer 22 is preferably attached to the fibrous face 20 of the first collagen layer 16 for placement against the mucosal surface to promote regeneration of mucosa. The second layer 22 can be formed of collagen I, II, III, IV, or VII any combination of these collagen types, but is preferably formed of predominantly collagen I, collagen II or a combination of collagen I and collagen III (e.g., 95% Type I collagen and 5% Type III collagen). The combination of the first and second layers 16 and 22 increases the thickness of the membrane 14' for easy handling and improved healing. The thickness of the membrane can vary depending upon application but will typically range from about 0.5 mm to about 5 mm, with a preferred range between about 2 mm and about 5 mm, and a thickness of about 3 mm being most preferred.
The first layer 16 in the embodiments shown in Figs. 2 and 3 can be produced in a variety of ways including, but not limited to, the process steps described in U.S.
Patent No.5,837,278; by de-airing and air-drying a slurry (film-like transparent membrane); by de-airing and vacuum-drying a slurry (film-like transparent membrane); or using compressed sponges. The first layer 16 can be made of collagen I, II, III or IV or combinations of these collagen types.
The second, sponge-like layer 22 in the embodiment shown in Fig. 3 is preferably a freeze-dryed collagen slurry.
The second layer 22 can be made of collagen I, II, III, IV or VII or combinations of these collagen types. Preferably, the second layer is made of collagen I, collagen II or a mixture of collagen I and III.
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates generally to methods for regeneration of mucosa.
Discussion of the Background Art The use of split thickness skin grafts and oral mucosal free grafts in vestibular deepening and other types of vestibuloplasty surgery in the oral cavity has been an established procedure for some time. In addition, the use of free mucosal grafts taken from the palate and from the buccal mucosa has been used in re-establishing attached mucosal surfaces in edentulous alveolar ridge areas particularly in conjunction with the use of root form implants.
While such grafting procedures are well established, the development of an effective alloplastic or xenogeniec substitute graft material for the reconstruction and regeneration of normal mucous membrane would bring about a much wider application of vestibuloplasty surgical procedures.
There remains a need in the art for improvements in promoting regeneration of mucosa in general and, in particular, following vestibuloplasty surgical procedures.
SUMMARY OF THE INVENTION
In accordance with the present invention, mucosa regeneration is promoted utilizing a membrane comprised of a purified collagen material derived from natural collagen-containing tissue.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a plan view showing a patch of collagen membrane material covering an area of mucosa to be treated.
FIG. 2 is a sectional side view showing a membrane for use in accordance with the present invention.
FIG. 3 is a sectional side view showing another membrane for use in accordance with the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention provides a method for promoting regeneration of mucosa. While the method is described in connection with promoting regeneration of mucosa in the oral cavity following specific types of oral surgery, it will be appreciated that the method can be employed to promote regeneration of mucosa in any part of the body having damaged mucosal tissue.
In preferred embodiments, a method of promoting regeneration of mucosa includes the steps of covering the area to be treated with a patch comprised of a sheet of collagen membrane material, wherein the collagen membrane material is comprised of at least one layer having a smooth face and a fibrous face opposite the smooth face, the fibrous face allowing cell growth thereon, wherein the collagen membrane preferably further comprises a second layer predominantly of collagen II or a mixture of collagen I and III having an open sponge-like texture. The patch is fixed over a defect in the mucosa, preferably with sutures, and the mucosa is allowed to regenerate.
In accordance with the present invention, as shown in Fig. 1, a defect in a mucosal surface M is repaired by placing a patch 10 over the defect and securing the patch to margins of the mucosal surface around the defect. The patched area is then allowed to regenerate mucosa. In Fig.
1, the patch 10 is shown secured by sutures 12 to the mucosal surface M. Alternatively, the patch can be secured over the defect by adhesively bonding the patch to the surrounding host mucosa or other structures surrounding the area to be treated, for example, utilizing an organic glue as is known in the art, or any other suitable method.
The patch 10 is formed of a preparation comprising a collagen membrane with appropriate pliability to conform closely to the shape of the mucosal surface against which it is placed. In a preferred embodiment, the collagen membrane includes at least one collagen layer having sufficient strength to accommodate suturing to the mucosa and to protect the mucosal surface from trauma during the healing process.
A first embodiment of a collagen membrane for use as a patch in accordance with the present invention is shown in Fig. 2 at 14. The membrane 14 includes a single collagen layer 16 having a smooth face 18 on one side and a textured or fibrous face 20 on the other side opposite the smooth face. The smooth face 18 is preferably non-porous to provide mechanical protection, for example when eating. The fibrous face 20 is configured to allow cell growth thereon. In use, the smooth face preferably is oriented away from the area to be treated, and the fibrous face preferably is oriented toward the area to be treated.
In preferred embodiments, the collagen layer 16 is predominantly collagen I, collagen III or a mixture thereof.
One suitable material for this layer is Biogide , from Ed.
Geistlich 561-me AG fUr Chemische Industrie, the assignee of the present invention. The Biogide material is described in U.S. Patent No. 5,837,278.
Fig. 3 shows a multi-layer collagen membrane 14' that can be used as a patch in accordance with the present invention. This membrane includes a first collagen layer 16 as shown in Fig. 2, and further includes a second collagen layer 22 having an open sponge-like texture. The second collagen layer 22 is preferably attached to the fibrous face 20 of the first collagen layer 16 for placement against the mucosal surface to promote regeneration of mucosa. The second layer 22 can be formed of collagen I, II, III, IV, or VII any combination of these collagen types, but is preferably formed of predominantly collagen I, collagen II or a combination of collagen I and collagen III (e.g., 95% Type I collagen and 5% Type III collagen). The combination of the first and second layers 16 and 22 increases the thickness of the membrane 14' for easy handling and improved healing. The thickness of the membrane can vary depending upon application but will typically range from about 0.5 mm to about 5 mm, with a preferred range between about 2 mm and about 5 mm, and a thickness of about 3 mm being most preferred.
The first layer 16 in the embodiments shown in Figs. 2 and 3 can be produced in a variety of ways including, but not limited to, the process steps described in U.S.
Patent No.5,837,278; by de-airing and air-drying a slurry (film-like transparent membrane); by de-airing and vacuum-drying a slurry (film-like transparent membrane); or using compressed sponges. The first layer 16 can be made of collagen I, II, III or IV or combinations of these collagen types.
The second, sponge-like layer 22 in the embodiment shown in Fig. 3 is preferably a freeze-dryed collagen slurry.
The second layer 22 can be made of collagen I, II, III, IV or VII or combinations of these collagen types. Preferably, the second layer is made of collagen I, collagen II or a mixture of collagen I and III.
The second collagen layer 22 may be formed from bovine or porcine material, and preferably is formed from porcine material.
In the embodiment shown in Fig. 3, the first and second membrane layers 16 and 22 can be connected to one another, or combined, in any suitable manner. Examples of three suitable methods of combination include: attaching the first membrane layer to the the second membrane layer with fibrin glue; attaching the first membrane layer to the second membrane layer using collagen slurry; or coating the first membrane layer with a collagen slurry of the desired collagen type for the second membrane layer, and then freeze-drying the combination.
If desired, growth factors such as EGF (Epidermal Growth Factor), IGF-1 (Insulin-like Growth Factor), 13-FGF
(Beta Fibroblast Growth Factor), PDGF (Platelet-derived Growth Factor), TGF-p (Transforming Growth Factor Beta) which promote mucosal regeneration, can be charged to the membrane, and/or added to the surface of the membrane that is placed against the mucosa.
Preparation of Patch (A) The first membrane layer is produced in accordance with the procedure described in WO 93/11723 (preparation of purified type I collagen, porcine skin). The final washed fibers are not freeze dried but the material is vacuum deaired and poured into a trace and dried in a laminar flow at room temperature.
(B) The second membrane layer is produced in accordance with the procedure described in WO 93/11723 (preparation of purified type I collagen, procine tendon). The final washed fibers are not freeze dried. They are acidificated again with hydrochloric acid to pH 2.9-3.2 to a dry content of 1.2-1.8%. This slurry is freeze dried to a sponge.
(C) The first and second membrane layers are combined by covering the first membrane layer on one side with the slurry pH 2.9-3.2 described above. Sponge on the slurry and freeze drying.
In the embodiment shown in Fig. 3, the first and second membrane layers 16 and 22 can be connected to one another, or combined, in any suitable manner. Examples of three suitable methods of combination include: attaching the first membrane layer to the the second membrane layer with fibrin glue; attaching the first membrane layer to the second membrane layer using collagen slurry; or coating the first membrane layer with a collagen slurry of the desired collagen type for the second membrane layer, and then freeze-drying the combination.
If desired, growth factors such as EGF (Epidermal Growth Factor), IGF-1 (Insulin-like Growth Factor), 13-FGF
(Beta Fibroblast Growth Factor), PDGF (Platelet-derived Growth Factor), TGF-p (Transforming Growth Factor Beta) which promote mucosal regeneration, can be charged to the membrane, and/or added to the surface of the membrane that is placed against the mucosa.
Preparation of Patch (A) The first membrane layer is produced in accordance with the procedure described in WO 93/11723 (preparation of purified type I collagen, porcine skin). The final washed fibers are not freeze dried but the material is vacuum deaired and poured into a trace and dried in a laminar flow at room temperature.
(B) The second membrane layer is produced in accordance with the procedure described in WO 93/11723 (preparation of purified type I collagen, procine tendon). The final washed fibers are not freeze dried. They are acidificated again with hydrochloric acid to pH 2.9-3.2 to a dry content of 1.2-1.8%. This slurry is freeze dried to a sponge.
(C) The first and second membrane layers are combined by covering the first membrane layer on one side with the slurry pH 2.9-3.2 described above. Sponge on the slurry and freeze drying.
Preparation of Patch (A) The first membrane layer is produced in accordance with the procedure described in U.S. Patent No. 5,837,278.
(B) The second membrane layer is produced in accordance with the procedure described in WO 99/19005, for the preparation of type II collagen slurry. Specifically, preparation of frozen cartilage from freshly slaughtered pigs to the washing step with cold water long enough for the pH value to rinse to pH 3-3.5. This material then is homogenized 5 times and diluted with water to get homogenous mass with a dry content of 0.5-2.0%.
(C) The first and second membrane layers are combined by pouring the slurry from the previous step on the first layer. After about 30 minutes, the combined product is freeze dried.
Preparation of Patch (A) The first membrane layer is produced in accordance with the procedure described in U.S. Patent No. 5,837,278.
(B) The second membrane layer is produced by treating defatted rinds from pigs with 1 N sodium hydroxide solution, for about 4 hours at about 20C, then treating with 1 N
hydrochloric acid solution, for about 2 hours at about 200, and homogenizing as described in Example 2.
(C) The first and second membrane layers are combined by pouring the slurry from the previous step on the first -7-.
=
layer. After about 30 minutes, the combined product is freeze dried.
Preparation of Patch (A) The first membrane layer is produced by drying the slurry gained in Example 3 through removal of the water with acetone, the acetone-wet product being pressed between two glass plates, and the acetones being removed with vacuum using a pressure of less than about 1 mBar, at about 35C, for about 48 hours.
(B) The second membrane layer is produced by mixing the slurries resulting from the second steps in Examples 2 and 3 in equal quantities, and freeze drying the mixture to a sponge.
(C) The first and second membrane layers are combined by glueing with a fibrin glue.
Testing The membrane material investigated was prepared from porcine Type I and Type III collagen manufactured in two layers. The deep or inner (second) layer of the collagen membrane has a roughened surface which is placed next to the host surgically prepared site to facilitate organization of the blood clot and to promote neoangiogenesis. The outer (first) layer of the bilayered collagen membrane has a smooth texture with appropriate elastic properties to accommodate suturing to the host mucosal margins and to protect the graft (patch) materials from oral trauma during the biodegrading and healing process. The sites utilized were all four oral mucosal quadrants of adult Papio anubis baboons. A 3 cm x 2 cm in diameter elliptical excisional wound was made to the submucosa in the depth of the canine and premolar vestibulaes. This model supplied twelve specimens for vestibular deepening sites evaluation.
Additionally, an area of attached mucosa of the edentulous maxilla was utilized to determine how effective the material would be when used as a basis for regaining attached mucous membrane in edentulous alveolar ridge areas.
lo An area 1 11 cm x 3 cm was dissected over the crest of the ridge extending from the buccal surface and crest of the ridge 1 cm over the palatal surface bilaterally in the three animals.
The membrane material was placed and secured to the margins of the host mucosal surface with a 4-0 monofilament nylon interrupted sutures. (The total number of sutures for each collagen membrane placement varied from 10 to 16). The animals were given antibiotic coverage post-operatively for four post-operative days consisting of Penicillin, Procaine 150,000 units and Bicillin'rm 150,000 units intramuscularly.
The animals were placed on a regular diet and were allowed free movement in large cages with runs.
Biopsies of the vestibular surgical sites were made at the end of three weeks and six weeks. At three weeks, a biopsy on one side (2 quadrants) of each animal was made to extend from the superior native residual host mucosal surface across the surface of the membrane material to the opposite inferior graft host margin. The surfaces of the specimens were appropriately tagged with sutures for orientation for histologic examination. The biopsy area was closed with interrupted sutures and allowed to heal. Two quadrants of each animal were allowed to remain for six weeks at which time the entire area was excised and the mucosal surface undermined and brought together to obtain primary closure.
Biopsies of the attached mucosal area were similarly taken: one side at 3 weeks and one side of each animal at 6 weeks for a total of three specimens for each period.
The sutures in all cases were removed on the 14' post-operative day. The clinical post-operative course of the animals was uneventful. There was no clinical evidence of inflammation or infection and no sloughing of the membrane material. The membrane remained in place and the margins indicated gradual re-epitheliazation from the host mucosal peripheral surfaces. Areas of residual membrane material were seen from the 2' through the 3 post-operative week clinically. At six weeks the entire surgical site had re-epithelized with a normal appearing mucosa.
The biopsies at the end of three weeks showed re-epitheliazation of the margins with normal retepeg formation.
Degrading areas of collagen with the epithelium migrating over the surface of the membrane were seen. In the center portion of the membrane measuring approximately .5 cm x .3 cm (from the original size of 3 x 2 cm) there was no re-epithelization.
In the 6-week specimens there was an excellent mucosal surface developed completely across the patched area with evidence of neoangiogensis submucosally and a normal stratified squamous epithelial formation in evidence with a complete excision and biopsy of the patched area. There was evidence of complete acceptance of the membrane material.
Very small areas of residual collagen could be seen beneath the surface epithelium. Stains utilized were Mason's Trichrome and Hematoxyclin and Eosin.
(B) The second membrane layer is produced in accordance with the procedure described in WO 99/19005, for the preparation of type II collagen slurry. Specifically, preparation of frozen cartilage from freshly slaughtered pigs to the washing step with cold water long enough for the pH value to rinse to pH 3-3.5. This material then is homogenized 5 times and diluted with water to get homogenous mass with a dry content of 0.5-2.0%.
(C) The first and second membrane layers are combined by pouring the slurry from the previous step on the first layer. After about 30 minutes, the combined product is freeze dried.
Preparation of Patch (A) The first membrane layer is produced in accordance with the procedure described in U.S. Patent No. 5,837,278.
(B) The second membrane layer is produced by treating defatted rinds from pigs with 1 N sodium hydroxide solution, for about 4 hours at about 20C, then treating with 1 N
hydrochloric acid solution, for about 2 hours at about 200, and homogenizing as described in Example 2.
(C) The first and second membrane layers are combined by pouring the slurry from the previous step on the first -7-.
=
layer. After about 30 minutes, the combined product is freeze dried.
Preparation of Patch (A) The first membrane layer is produced by drying the slurry gained in Example 3 through removal of the water with acetone, the acetone-wet product being pressed between two glass plates, and the acetones being removed with vacuum using a pressure of less than about 1 mBar, at about 35C, for about 48 hours.
(B) The second membrane layer is produced by mixing the slurries resulting from the second steps in Examples 2 and 3 in equal quantities, and freeze drying the mixture to a sponge.
(C) The first and second membrane layers are combined by glueing with a fibrin glue.
Testing The membrane material investigated was prepared from porcine Type I and Type III collagen manufactured in two layers. The deep or inner (second) layer of the collagen membrane has a roughened surface which is placed next to the host surgically prepared site to facilitate organization of the blood clot and to promote neoangiogenesis. The outer (first) layer of the bilayered collagen membrane has a smooth texture with appropriate elastic properties to accommodate suturing to the host mucosal margins and to protect the graft (patch) materials from oral trauma during the biodegrading and healing process. The sites utilized were all four oral mucosal quadrants of adult Papio anubis baboons. A 3 cm x 2 cm in diameter elliptical excisional wound was made to the submucosa in the depth of the canine and premolar vestibulaes. This model supplied twelve specimens for vestibular deepening sites evaluation.
Additionally, an area of attached mucosa of the edentulous maxilla was utilized to determine how effective the material would be when used as a basis for regaining attached mucous membrane in edentulous alveolar ridge areas.
lo An area 1 11 cm x 3 cm was dissected over the crest of the ridge extending from the buccal surface and crest of the ridge 1 cm over the palatal surface bilaterally in the three animals.
The membrane material was placed and secured to the margins of the host mucosal surface with a 4-0 monofilament nylon interrupted sutures. (The total number of sutures for each collagen membrane placement varied from 10 to 16). The animals were given antibiotic coverage post-operatively for four post-operative days consisting of Penicillin, Procaine 150,000 units and Bicillin'rm 150,000 units intramuscularly.
The animals were placed on a regular diet and were allowed free movement in large cages with runs.
Biopsies of the vestibular surgical sites were made at the end of three weeks and six weeks. At three weeks, a biopsy on one side (2 quadrants) of each animal was made to extend from the superior native residual host mucosal surface across the surface of the membrane material to the opposite inferior graft host margin. The surfaces of the specimens were appropriately tagged with sutures for orientation for histologic examination. The biopsy area was closed with interrupted sutures and allowed to heal. Two quadrants of each animal were allowed to remain for six weeks at which time the entire area was excised and the mucosal surface undermined and brought together to obtain primary closure.
Biopsies of the attached mucosal area were similarly taken: one side at 3 weeks and one side of each animal at 6 weeks for a total of three specimens for each period.
The sutures in all cases were removed on the 14' post-operative day. The clinical post-operative course of the animals was uneventful. There was no clinical evidence of inflammation or infection and no sloughing of the membrane material. The membrane remained in place and the margins indicated gradual re-epitheliazation from the host mucosal peripheral surfaces. Areas of residual membrane material were seen from the 2' through the 3 post-operative week clinically. At six weeks the entire surgical site had re-epithelized with a normal appearing mucosa.
The biopsies at the end of three weeks showed re-epitheliazation of the margins with normal retepeg formation.
Degrading areas of collagen with the epithelium migrating over the surface of the membrane were seen. In the center portion of the membrane measuring approximately .5 cm x .3 cm (from the original size of 3 x 2 cm) there was no re-epithelization.
In the 6-week specimens there was an excellent mucosal surface developed completely across the patched area with evidence of neoangiogensis submucosally and a normal stratified squamous epithelial formation in evidence with a complete excision and biopsy of the patched area. There was evidence of complete acceptance of the membrane material.
Very small areas of residual collagen could be seen beneath the surface epithelium. Stains utilized were Mason's Trichrome and Hematoxyclin and Eosin.
Multiple sections were taken on the six week specimens to enable complete evaluation of the entire patched areas so that no residual membrane material would be undetected in the histologic examination process.
The patch, when placed in the posterior alveolar ridge and palatal maxillary surface, indicated a replacement of the membrane material similar to that seen in the vestibular depth type of test site. At three weeks there was evidence of residual membrane material which was in the center portion of the patched site. Fibroblasts and migrating epithelium could be seen from the peripheral margins of the patched site. In the six week specimens, new attached mucosa could be seen in all of the specimens on the palatal surface, on the alveolar ridge crest, and on the buccal aspect of the alveolar ridge. This indicated complete acceptance of the material and excellent re-reformation of attached mucosa.
The histologic appearance indicated that this material in the maxillary posterior area cold be used to re-establish attached mucosa in conjunction with root form implants although this area of efficacy was not specifically studied in this test.
The sites selected in the animals for vestibular grafting were in the maxillary and mandibular canine and premolar vestibular mucosal region. This area is particularly prone to trauma in the Papio anubis baboon during feeding and mastication and would serve as a stress-producing test site. Thus the material was placed in a situation which there was a high possibly of insult with resulting infection and dislodgement of the patch. This did not occur in any of the test sites and materials remained in place and were biodegraded by a very mild process of host cellular activity.
The patch, when placed in the posterior alveolar ridge and palatal maxillary surface, indicated a replacement of the membrane material similar to that seen in the vestibular depth type of test site. At three weeks there was evidence of residual membrane material which was in the center portion of the patched site. Fibroblasts and migrating epithelium could be seen from the peripheral margins of the patched site. In the six week specimens, new attached mucosa could be seen in all of the specimens on the palatal surface, on the alveolar ridge crest, and on the buccal aspect of the alveolar ridge. This indicated complete acceptance of the material and excellent re-reformation of attached mucosa.
The histologic appearance indicated that this material in the maxillary posterior area cold be used to re-establish attached mucosa in conjunction with root form implants although this area of efficacy was not specifically studied in this test.
The sites selected in the animals for vestibular grafting were in the maxillary and mandibular canine and premolar vestibular mucosal region. This area is particularly prone to trauma in the Papio anubis baboon during feeding and mastication and would serve as a stress-producing test site. Thus the material was placed in a situation which there was a high possibly of insult with resulting infection and dislodgement of the patch. This did not occur in any of the test sites and materials remained in place and were biodegraded by a very mild process of host cellular activity.
=
On the basis of these tests, it was concluded that use of a collagen membrane as a patch according to the present invention is an excellent substitute for autogenous soft tissue grafts. Some types of alloplastic or allogeneic surface dressings tend to produce a contracture of wound and scar formation. Also there is tendency for artificial skin surface dressings to either biodegrade and slough prematurely or to remain for prolonged period of time with a delayed inflammatory response. There was no evidence of either scarring or prolonged inflammatory response with the present invention. Neither was there any evidence of submucosal fibrosis which sometimes occurs in the use of surgical dressings.
Thus, it appears that this material could be used as a substitute for free mucosal grafts or split thickness skin grafts in maintaining the vestibular height and in the restoration of attached mucosa in the area of root form implants. Some of the apparent advantages of this method are that the membrane will (a) biodegrade without an adverse inflammatory response, (b) promote regeneration of the area with normal mucosa, and (c) be technically feasible in surgical manipulation and exhibit tolerance to suturing.
Since many modifications, variations and changes in detail may be made to the described embodiments, it is intended that all matter in the foregoing description and shown in the accompanying drawings be interpreted as illustrative and not in a limiting sense.
On the basis of these tests, it was concluded that use of a collagen membrane as a patch according to the present invention is an excellent substitute for autogenous soft tissue grafts. Some types of alloplastic or allogeneic surface dressings tend to produce a contracture of wound and scar formation. Also there is tendency for artificial skin surface dressings to either biodegrade and slough prematurely or to remain for prolonged period of time with a delayed inflammatory response. There was no evidence of either scarring or prolonged inflammatory response with the present invention. Neither was there any evidence of submucosal fibrosis which sometimes occurs in the use of surgical dressings.
Thus, it appears that this material could be used as a substitute for free mucosal grafts or split thickness skin grafts in maintaining the vestibular height and in the restoration of attached mucosa in the area of root form implants. Some of the apparent advantages of this method are that the membrane will (a) biodegrade without an adverse inflammatory response, (b) promote regeneration of the area with normal mucosa, and (c) be technically feasible in surgical manipulation and exhibit tolerance to suturing.
Since many modifications, variations and changes in detail may be made to the described embodiments, it is intended that all matter in the foregoing description and shown in the accompanying drawings be interpreted as illustrative and not in a limiting sense.
Claims (9)
1. Use of a patch for promoting mucosa regeneration in an area of mucosa injury, wherein the patch comprises a collagen membrane containing collagen material purified from natural collagen-containing tissue, the collagen membrane having two layers, a first collagen layer and a second collagen layer, the first collagen layer having a smooth face on one side and a fibrous face on the other side opposite to said smooth face, the smooth face being non-porous, the fibrous face being configured to allow cell growth thereon, the second collagen layer having an open sponge-like texture, and being attached to the fibrous face of the first collagen layer, and wherein the second collagen layer is for placement against the area of mucosa injury for promoting mucosa regeneration.
2. The use of claim 1, wherein said first collagen layer is predominantly collagen I, collagen III or any mixture thereof.
3. The use of claim 1 or 2, wherein said second collagen layer comprises collagen I, collagen II, collagen III, collagen IV, collagen VII or any combination thereof.
4. The use of claim 1, 2 or 3, wherein said patch has a thickness of about 0.5 - 5 mm.
5. The use of claim 4, wherein said second collagen layer comprises predominantly collagen I.
6. The use of claim 4, wherein said second collagen layer comprises predominantly collagen II.
7. The use of any one of claims 1 to 6, wherein said patch carries at least one mucosa-regenerating growth factor.
8. The use of claim 7, wherein said at least one growth factor is Epidermal Growth Factor (EGF), Insulin-like Growth Factor (IGF-I), Beta Fibroblast Growth Factor (.beta.-FGF), Platelet-derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-.beta.), or any mixture thereof.
9. The use of any one of claims 1 to 8, wherein said mucosa injury is an oral mucosa injury.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28653101P | 2001-04-27 | 2001-04-27 | |
US60/286,531 | 2001-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2383636A1 CA2383636A1 (en) | 2002-10-27 |
CA2383636C true CA2383636C (en) | 2014-07-22 |
Family
ID=23099039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2383636A Expired - Lifetime CA2383636C (en) | 2001-04-27 | 2002-04-26 | Collagen membrane for mucosa regeneration |
Country Status (14)
Country | Link |
---|---|
US (1) | US6713085B2 (en) |
EP (2) | EP1252903B1 (en) |
JP (1) | JP4285940B2 (en) |
CN (1) | CN1253213C (en) |
AT (2) | ATE462452T1 (en) |
AU (1) | AU784394B2 (en) |
CA (1) | CA2383636C (en) |
CZ (1) | CZ302044B6 (en) |
DE (2) | DE60216353T2 (en) |
DK (2) | DK1709981T3 (en) |
ES (2) | ES2342677T3 (en) |
PL (1) | PL206261B1 (en) |
PT (1) | PT1252903E (en) |
RU (1) | RU2288001C2 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050186673A1 (en) * | 1995-02-22 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
US9034315B2 (en) * | 1997-10-10 | 2015-05-19 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Cell-charged multi-layer collagen membrane |
US20050186283A1 (en) * | 1997-10-10 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
US20050147690A1 (en) * | 1998-09-25 | 2005-07-07 | Masters David B. | Biocompatible protein particles, particle devices and methods thereof |
US8673333B2 (en) * | 2002-09-25 | 2014-03-18 | The Johns Hopkins University | Cross-linked polymer matrices, and methods of making and using same |
US7862831B2 (en) * | 2002-10-09 | 2011-01-04 | Synthasome, Inc. | Method and material for enhanced tissue-biomaterial integration |
US20040136968A1 (en) * | 2002-09-27 | 2004-07-15 | Verigen Ag | Autologous cells on a support matrix for tissue repair |
US20050069572A1 (en) * | 2002-10-09 | 2005-03-31 | Jennifer Elisseeff | Multi-layered polymerizing hydrogels for tissue regeneration |
TW200505394A (en) * | 2003-06-06 | 2005-02-16 | Asahi Medical Co | Material promoting wound healing |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
WO2006089119A2 (en) * | 2005-02-18 | 2006-08-24 | Cartilix, Inc. | Biological adhesive |
US8084428B2 (en) | 2005-09-02 | 2011-12-27 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of repairing meniscal tears |
US7591841B2 (en) * | 2005-12-16 | 2009-09-22 | Advanced Cardiovascular Systems, Inc. | Implantable devices for accelerated healing |
ATE464916T1 (en) * | 2006-11-06 | 2010-05-15 | Lohmann & Rauscher Gmbh & Co Kg | PRODUCT FOR THE TREATMENT OF INFLAMMATION, PRESSURE SORES AND/OR APHATOES IN THE ORAL AREA AND USE OF SUCH A PRODUCT |
PT2097116E (en) | 2006-12-22 | 2012-12-06 | Medidom Lab | In situ system for intra-articular chondral and osseous tissue repair |
US9056151B2 (en) * | 2007-02-12 | 2015-06-16 | Warsaw Orthopedic, Inc. | Methods for collagen processing and products using processed collagen |
US20080260794A1 (en) * | 2007-02-12 | 2008-10-23 | Lauritzen Nels J | Collagen products and methods for producing collagen products |
DE102007009095A1 (en) * | 2007-02-24 | 2008-08-28 | Gfe Nanomedical International Ag | A method of treating biological tissues of animal or human origin, such as porcine, bovine pericardial or human coronary heart valves, and appropriately treated biological tissue |
JP5698680B2 (en) * | 2009-01-16 | 2015-04-08 | ガイストリヒ・ファーマ・アクチェンゲゼルシャフトGeistlich Pharma Ag | Method and membrane for skin regeneration |
US8790699B2 (en) | 2010-04-23 | 2014-07-29 | Warsaw Orthpedic, Inc. | Foam-formed collagen strand |
US8460691B2 (en) | 2010-04-23 | 2013-06-11 | Warsaw Orthopedic, Inc. | Fenestrated wound repair scaffold |
US10071184B2 (en) * | 2012-02-29 | 2018-09-11 | Collagen Matrix, Inc. | Collagen-coated tissue-based membranes |
US9644177B2 (en) * | 2012-07-12 | 2017-05-09 | Board Of Regents, The University Of Texas System | Extracellular matrix films and methods of making and using same |
CN103341211B (en) * | 2013-06-14 | 2014-10-29 | 张仲文 | Preparation method for I/II collagen double-layer composite collagen membrane |
EP3034103A1 (en) * | 2014-12-15 | 2016-06-22 | Geistlich Pharma AG | Collagen Sponge |
EP3175869A1 (en) * | 2015-12-04 | 2017-06-07 | Geistlich Pharma AG | Resorbable crosslinked formstable membrane |
US10869949B2 (en) * | 2019-04-11 | 2020-12-22 | Geistlich Pharma Ag | Method for treating subjects suffering from chronic ulcers |
DE102019123799B4 (en) | 2019-09-05 | 2021-11-04 | Universität Bremen | Process for the production of biomaterials with porous and smooth topographies and their use |
WO2022079186A1 (en) | 2020-10-15 | 2022-04-21 | Geistlich Pharma Ag | Applicator of a spongeous collagen membrane and kit comprising such applicator and membrane |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4772470A (en) * | 1985-04-27 | 1988-09-20 | Nitto Electric Industrial Co., Ltd. | Oral bandage and oral preparations |
US5306311A (en) * | 1987-07-20 | 1994-04-26 | Regen Corporation | Prosthetic articular cartilage |
US4880429A (en) | 1987-07-20 | 1989-11-14 | Stone Kevin R | Prosthetic meniscus |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
WO1990013302A1 (en) | 1989-04-28 | 1990-11-15 | Brigham And Women's Hospital | Novel materials and methods for guided tissue regeneration |
CS277367B6 (en) | 1990-12-29 | 1993-01-13 | Krajicek Milan | Three-layered vascular prosthesis |
US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
FR2679778B1 (en) | 1991-08-02 | 1995-07-07 | Coletica | USE OF CROLAGEN CROSSLINKED BY A CROSSLINKING AGENT FOR THE MANUFACTURE OF A SLOW RESORPTIVE, BIOCOMPATIBLE, SUTURABLE MEMBRANE, AS WELL AS SUCH A MEMBRANE. |
EP0614345A4 (en) | 1991-11-26 | 1994-12-07 | Res Dev Foundation | Fetal membrane tubes for nerve and vessel grafts. |
US5326357A (en) | 1992-03-18 | 1994-07-05 | Mount Sinai Hospital Corporation | Reconstituted cartridge tissue |
GB9400163D0 (en) * | 1994-01-06 | 1994-03-02 | Geistlich Soehne Ag | Membrane |
US5891558A (en) | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
US6080194A (en) | 1995-02-10 | 2000-06-27 | The Hospital For Joint Disease Orthopaedic Institute | Multi-stage collagen-based template or implant for use in the repair of cartilage lesions |
GB9503492D0 (en) | 1995-02-22 | 1995-04-12 | Ed Geistlich S Hne A G F R Che | Chemical product |
GB9721585D0 (en) | 1997-10-10 | 1997-12-10 | Geistlich Soehne Ag | Chemical product |
US6352558B1 (en) | 1996-02-22 | 2002-03-05 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method for promoting regeneration of surface cartilage in a damage joint |
US5759190A (en) | 1996-08-30 | 1998-06-02 | Vts Holdings Limited | Method and kit for autologous transplantation |
US5989269A (en) | 1996-08-30 | 1999-11-23 | Vts Holdings L.L.C. | Method, instruments and kit for autologous transplantation |
US6120514A (en) | 1996-08-30 | 2000-09-19 | Vts Holdings, Llc | Method and kit for autologous transplantation |
WO1999060951A1 (en) * | 1998-05-22 | 1999-12-02 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has degenerated, and methods for using such compositions |
US6300315B1 (en) | 1999-08-28 | 2001-10-09 | Ceramedical, Inc. | Mineralized collagen membrane and method of making same |
US6221109B1 (en) | 1999-09-15 | 2001-04-24 | Ed. Geistlich Söhne AG fur Chemische Industrie | Method of protecting spinal area |
-
2002
- 2002-04-24 US US10/128,525 patent/US6713085B2/en not_active Expired - Lifetime
- 2002-04-24 AU AU35618/02A patent/AU784394B2/en not_active Expired
- 2002-04-26 EP EP02252970A patent/EP1252903B1/en not_active Expired - Lifetime
- 2002-04-26 AT AT06011350T patent/ATE462452T1/en not_active IP Right Cessation
- 2002-04-26 ES ES06011350T patent/ES2342677T3/en not_active Expired - Lifetime
- 2002-04-26 AT AT02252970T patent/ATE346620T1/en active
- 2002-04-26 JP JP2002125350A patent/JP4285940B2/en not_active Expired - Fee Related
- 2002-04-26 CZ CZ20021479A patent/CZ302044B6/en not_active IP Right Cessation
- 2002-04-26 ES ES02252970T patent/ES2275810T3/en not_active Expired - Lifetime
- 2002-04-26 DK DK06011350.3T patent/DK1709981T3/en active
- 2002-04-26 PL PL353657A patent/PL206261B1/en unknown
- 2002-04-26 DE DE60216353T patent/DE60216353T2/en not_active Expired - Lifetime
- 2002-04-26 CA CA2383636A patent/CA2383636C/en not_active Expired - Lifetime
- 2002-04-26 DE DE60235845T patent/DE60235845D1/en not_active Expired - Lifetime
- 2002-04-26 PT PT02252970T patent/PT1252903E/en unknown
- 2002-04-26 DK DK02252970T patent/DK1252903T3/en active
- 2002-04-26 EP EP06011350A patent/EP1709981B1/en not_active Expired - Lifetime
- 2002-04-27 RU RU2002111375/15A patent/RU2288001C2/en active
- 2002-04-27 CN CNB021184984A patent/CN1253213C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2342677T3 (en) | 2010-07-12 |
AU784394B2 (en) | 2006-03-23 |
US20020160036A1 (en) | 2002-10-31 |
AU3561802A (en) | 2002-10-31 |
JP2003010313A (en) | 2003-01-14 |
CZ302044B6 (en) | 2010-09-15 |
DK1709981T3 (en) | 2010-06-28 |
DE60216353D1 (en) | 2007-01-11 |
EP1709981B1 (en) | 2010-03-31 |
RU2288001C2 (en) | 2006-11-27 |
DE60235845D1 (en) | 2010-05-12 |
CN1253213C (en) | 2006-04-26 |
ATE462452T1 (en) | 2010-04-15 |
CA2383636A1 (en) | 2002-10-27 |
CZ20021479A3 (en) | 2003-04-16 |
EP1252903B1 (en) | 2006-11-29 |
EP1252903A1 (en) | 2002-10-30 |
ES2275810T3 (en) | 2007-06-16 |
US6713085B2 (en) | 2004-03-30 |
DK1252903T3 (en) | 2006-12-27 |
PL353657A1 (en) | 2002-11-04 |
RU2002111375A (en) | 2004-01-27 |
EP1709981A1 (en) | 2006-10-11 |
PT1252903E (en) | 2007-02-28 |
JP4285940B2 (en) | 2009-06-24 |
ATE346620T1 (en) | 2006-12-15 |
DE60216353T2 (en) | 2007-05-03 |
CN1383897A (en) | 2002-12-11 |
PL206261B1 (en) | 2010-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2383636C (en) | Collagen membrane for mucosa regeneration | |
CA2749888C (en) | Method and membrane for tissue regeneration | |
Alpaslan et al. | Tissue reaction to three subcutaneously implanted local hemostatic agents | |
CN1034630C (en) | Composition inducing binding | |
JPH11508151A (en) | Bladder reconstruction method and tissue graft for bladder reconstruction | |
AU2009202536A1 (en) | Composite material for wound repair | |
JP2004026653A (en) | Hemostatic composition of hydroxyapatite polymer composite material | |
RU2367475C1 (en) | Membrane to be used in targeted angiogenesis | |
CN112107390B (en) | Composite tendon repair material and preparation method thereof | |
WO2020017661A1 (en) | Medical film material | |
RU2003112493A (en) | WAY TREATMENT METHOD AFTER REMOVING A TOOTH OR IMPLANT | |
Chen et al. | Clinical evaluation of a new bilayer artificial dermis for repair of oral mucosal defects: report of two cases | |
JPH10139684A (en) | Periodontal tissue regeneration promoter and dental material for promotion | |
Dangi | Collagen as a Biological Dressing for Denuded Areas–A Clinical Study | |
de Oliveria Lima et al. | The Use of Homogenous Dura Mater in the Excision of Epulis Fissurata. | |
송건영 | The effect of collagen and chitosan membrane coated with PLGA on bone regeneration in rat calvarial defects | |
CZ193588A3 (en) | Preparation for regeneration of mineralized tissue and process for preparing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20220426 |